These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 18941649)

  • 1. Low incidence of neurologic events during long-term support with the HeartMate XVE left ventricular assist device.
    Slaughter MS; Sobieski MA; Gallagher C; Dia M; Silver MA
    Tex Heart Inst J; 2008; 35(3):245-9. PubMed ID: 18941649
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improved survival and decreasing incidence of adverse events with the HeartMate II left ventricular assist device as bridge-to-transplant therapy.
    John R; Kamdar F; Liao K; Colvin-Adams M; Boyle A; Joyce L
    Ann Thorac Surg; 2008 Oct; 86(4):1227-34; discussion 1234-5. PubMed ID: 18805167
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of left ventricular assist device (HeartMate II): a Singapore experience.
    Lim CP; Sivathasan C; Tan TE; Lim CH; Kerk KL; Sim DK
    Artif Organs; 2014 Jul; 38(7):543-8. PubMed ID: 24392937
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low thromboembolic risk for patients with the Heartmate II left ventricular assist device.
    John R; Kamdar F; Liao K; Colvin-Adams M; Miller L; Joyce L; Boyle A
    J Thorac Cardiovasc Surg; 2008 Nov; 136(5):1318-23. PubMed ID: 19026822
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The spectrum of complications following left ventricular assist device placement.
    Yuan N; Arnaoutakis GJ; George TJ; Allen JG; Ju DG; Schaffer JM; Russell SD; Shah AS; Conte JV
    J Card Surg; 2012 Sep; 27(5):630-8. PubMed ID: 22978843
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Post-cardiac transplant survival after support with a continuous-flow left ventricular assist device: impact of duration of left ventricular assist device support and other variables.
    John R; Pagani FD; Naka Y; Boyle A; Conte JV; Russell SD; Klodell CT; Milano CA; Rogers J; Farrar DJ; Frazier OH
    J Thorac Cardiovasc Surg; 2010 Jul; 140(1):174-81. PubMed ID: 20447659
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is anti-platelet therapy needed in continuous flow left ventricular assist device patients? A single-centre experience.
    Litzler PY; Smail H; Barbay V; Nafeh-Bizet C; Bouchart F; Baste JM; Abriou C; Bessou JP
    Eur J Cardiothorac Surg; 2014 Jan; 45(1):55-9; discussion 59-60. PubMed ID: 23671203
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improved durability of the HeartMate XVE left ventricular assist device provides safe mechanical support up to 1 year but is associated with high risk of device failure in the second year.
    Martin J; Friesewinkel O; Benk C; Sorg S; Schultz S; Beyersdorf F
    J Heart Lung Transplant; 2006 Apr; 25(4):384-90. PubMed ID: 16563965
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ischemic versus nonischemic dilated cardiomyopathy: the implications of heart failure etiology on left ventricular assist device outcomes.
    Tsiouris A; Borgi J; Karam J; Nemeh HW; Paone G; Brewer RJ; Morgan JA
    ASAIO J; 2013; 59(2):130-5. PubMed ID: 23438774
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thoratec implantable ventricular assist device: the Papworth experience.
    Berman M; Parameshwar J; Jenkins DP; Dhital K; Lewis C; Dempster K; Lincoln P; Sudarshan C; Large SR; Dunning J; Tsui SS
    J Thorac Cardiovasc Surg; 2010 Feb; 139(2):466-73. PubMed ID: 19833355
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Results of the post-U.S. Food and Drug Administration-approval study with a continuous flow left ventricular assist device as a bridge to heart transplantation: a prospective study using the INTERMACS (Interagency Registry for Mechanically Assisted Circulatory Support).
    Starling RC; Naka Y; Boyle AJ; Gonzalez-Stawinski G; John R; Jorde U; Russell SD; Conte JV; Aaronson KD; McGee EC; Cotts WG; DeNofrio D; Pham DT; Farrar DJ; Pagani FD
    J Am Coll Cardiol; 2011 May; 57(19):1890-8. PubMed ID: 21545946
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical experience with sternotomy versus subcostal approach for exchange of the HeartMate XVE to the HeartMate II ventricular assist device.
    Gregoric ID; Bruckner BA; Jacob L; Kar B; Cohn WE; La Francesca S; Frazier OH
    Ann Thorac Surg; 2008 May; 85(5):1646-9. PubMed ID: 18442556
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcomes of left ventricular assist device implantation as destination therapy in the post-REMATCH era: implications for patient selection.
    Lietz K; Long JW; Kfoury AG; Slaughter MS; Silver MA; Milano CA; Rogers JG; Naka Y; Mancini D; Miller LW
    Circulation; 2007 Jul; 116(5):497-505. PubMed ID: 17638928
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Post-operative heparin may not be required for transitioning patients with a HeartMate II left ventricular assist system to long-term warfarin therapy.
    Slaughter MS; Naka Y; John R; Boyle A; Conte JV; Russell SD; Aaronson KD; Sundareswaran KS; Farrar DJ; Pagani FD
    J Heart Lung Transplant; 2010 Jun; 29(6):616-24. PubMed ID: 20400335
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Continuous-flow left ventricular assist device therapy in patients with preoperative hepatic failure: are we pushing the limits too far?
    Weymann A; Patil NP; Sabashnikov A; Mohite PN; Garcia Saez D; Bireta C; Wahlers T; Karck M; Kallenbach K; Ruhparwar A; Fatullayev J; Amrani M; De Robertis F; Bahrami T; Popov AF; Simon AR
    Artif Organs; 2015 Apr; 39(4):336-42. PubMed ID: 25345547
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neurocognitive function in destination therapy patients receiving continuous-flow vs pulsatile-flow left ventricular assist device support.
    Petrucci RJ; Rogers JG; Blue L; Gallagher C; Russell SD; Dordunoo D; Jaski BE; Chillcott S; Sun B; Yanssens TL; Tatooles A; Koundakjian L; Farrar DJ; Slaughter MS
    J Heart Lung Transplant; 2012 Jan; 31(1):27-36. PubMed ID: 22153550
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term destination therapy with the HeartMate XVE left ventricular assist device: improved outcomes since the REMATCH study.
    Long JW; Kfoury AG; Slaughter MS; Silver M; Milano C; Rogers J; Delgado R; Frazier OH
    Congest Heart Fail; 2005; 11(3):133-8. PubMed ID: 15947534
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of centrifugal, axial, and pulsatile left ventricular assist device support on end-organ function in heart failure patients.
    Kamdar F; Boyle A; Liao K; Colvin-adams M; Joyce L; John R
    J Heart Lung Transplant; 2009 Apr; 28(4):352-9. PubMed ID: 19332262
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Left ventricular assist device recipients at risk of right ventricular failure: the role of a planned temporary biventricular support].
    Loforte A; Lilla Della Monica P; Montalto A; Musumeci F
    G Ital Cardiol (Rome); 2011 Dec; 12(12):839-45. PubMed ID: 22158456
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Experience with the HeartMate II Left Ventricular Assist Device in Patients Older than 60 Years.
    Demirozu ZT; Critsinelis A; Cohn WE; Radovancevic R; Ho J; Hernandez R; Morgan JA; Frazier OH
    Heart Surg Forum; 2019 Mar; 22(2):E124-E130. PubMed ID: 31013222
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.